Proctofoam-HC®
DrugObservational study of the exposure to Proctofoam-HC®
Other names: 1% Pramoxine+1% Hydrocortisone ( Proctofoam-HC®)
NCT Number: NCT00405288
The purpose of this study is to evaluate the fetal safety of topical application of Proctofoam-HC®, an antihemorrhoidal, in the third trimester of pregnancy.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Mount Sinai Hospital, Toronto, Ontario, Canada
Hemorrhoids are a frequent condition in pregnancy. The rate is increased as pregnancy progresses, and they affect up to 24% of pregnant women in the third trimester. Complications of untreated hemorrhoids include bleeding, prolapse, soiling, discharge with perianal irritation and itching, and in severe cases, severe pain and venous engorgement which could even lead to thrombosis and infarction. Hemorrhoids are treated with a variety of suppositories and gels, based on analgesic and anti-inflammatory effects. The safety of these antihemorrhoidal products has not yet been documented in pregnant women.
Proctofoam-HC® has been on the Canadian market for 25 years. It combines the anti-inflammatory action of hydrocortisone with the surface anesthetic effect of pramoxine HCl. It is approved for temporary relief of anorectal inflammation, pruritus, pain and swelling associated with haemorrhoids, fissures, pruritus ani, cryptitis, proctitis and postoperative pain.
We hypothesize that local application of Proctofoam-HC® in the third trimester of pregnancy is safe for the mother and fetus.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Observational study of the exposure to Proctofoam-HC®
Other names: 1% Pramoxine+1% Hydrocortisone ( Proctofoam-HC®)
Time frame: until delivery
Weight of the baby measured in grams at time of birth.
Time frame: until delivery
Fetal gestational age at delivery
Time frame: at birth
Method of delivery for both groups: vaginal or caesarean section
Time frame: at birth
birth at <37 gestational weeks
Time frame: at birth
Presence of fetal distress at birth: heart deceleration/acceleration, meconium/amniotic fluid
Time frame: at birth
Low birth weight (birth weights <2500 grams)
Time frame: at birth
Neonatal health at birthyes=need for medical attention or intervention after birth, abnormalities detected, no= no need for medical attention, no abnormalities detected at birth
The Hospital for Sick Children
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06860100
Cardiovascular Diseases, Digestive System Diseases
Van, Tuşba, Turkey (Türkiye)
View Trial DetailsNCT05089500
Cardiovascular Diseases, Digestive System Diseases
Wuhan, Hubei, China
View Trial DetailsNCT01881282
Cardiovascular Diseases, Digestive System Diseases
Beijing, China
View Trial DetailsNCT05519189
Cardiovascular Diseases, Digestive System Diseases
La Roche-sur-Yon, France
View Trial Details